Are China Hospital Purchases Slowing? Ask Mindray
This article was originally published in PharmAsia News
China’s largest medical device maker surprised everyone by posting overall second-quarter net revenue growth of 9% to $334.5 million amid challenging market conditions. It expects a further recovery in the second half, but conditions at home remain difficult.
You may also be interested in...
The latest developments in a US Congressional draft bill to curb Chinese biotech operations in the US is separating contract manufacturing and research from gene sequencing service providers, which may give China's major contract players reasons to breathe easy.
Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.
10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.